Abstract:Over the past ten years, the incidence rate of papillary thyroid carcinoma (PTC) worldwide has been increasing rapidly year by year, with the incidence rate increasing 6% annually. PTC has become the malignant tumor with the highest growth rate in the world that fourteen PTC-related mutant genes have been identified. Whether the BRAFV600E mutation related to more aggressive clinicopathologic features and worse outcome in PTC remains variable and controversial. We aim to investigate the risk factors that may predict the BRAFV600E mutation potential of these lesions and new prevention strategies in PTC patients.A total of 9,908 papillary thyroid carcinoma patients with average 74.6% BRAFV600E mutations were analyzed (RevMan 5.3 software) in this study. The PubMed, Embase, and ISI Web of Science databases were systematically searched for works published through December 15, 2021.The following variables were associated with an increased risk of BRAFV600E mutation in PTC patients: age ≥ 45 years (OR = 1.39, 95%CI = 1.21-1.60, p < 0.00001), male gender (OR = 1.13, 95%CI = 0.99-1.28, p = 0.06), multifocality (OR = 1.22, 95%CI = 1.07-1.40, p = 0.004), lymph node metastasis (OR = 1.33, 95%CI = 0.79-2.23, p = 0.28), extrathyroidal extension + (OR = 1.61, 95%CI = 1.06-2.44, p = 0.03), vascular invasion + (OR = 2.04, 95%CI = 1.32-3.15, p = 0.001), and tumor node metastasis stage (OR = 1.61, 95%CI = 1.38-1.88, p < 0.00001). In addition, tumor size (>1 cm) (OR = 0.51, 95%CI = 0.32-0.81, p = 0.005) and distant metastasis (OR = 0.69, 95%CI = 0.22-2.21, p = 0.54) had no association or risk with BRAFV600E mutation in PTC patients.Our systematic review identified the following significant risk factors of BRAFV600E mutation in PTC patients: age (≥45 years), gender (male), multifocality, lymph node metastasis, vascular invasion, extrathyroidal extension, and advanced tumor node metastasis stage (stages III and IV). Tumor size (>1 cm) and distant metastasis do not appear to be correlated with BRAFV600E mutation in PTC patients.

Relationship Between BRAFV600E Gene and TERT Promoter Mutations with Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer with BRAF V600E Mutation.

Association of Telomerase Reverse Transcriptase Promoter Mutations with Clinicopathological Features and Prognosis of Thyroid Cancer: a Meta-Analysis.

Use of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules

The Predictive Value Of Coexisting Brafv600e And Tert Promoter Mutations On Poor Outcomes And High Tumour Aggressiveness In Papillary Thyroid Carcinoma: A Systematic Review And Meta-Analysis

TERTPromoter Mutations and Their Association Withbrafv600e Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer

TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer.

Brafv600e Mutation in Papillary Thyroid Microcarcinoma: A Meta-Analysis

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma

Suspicious Ultrasound and Clinicopathological Features of Papillary Thyroid Carcinoma Predict the Status of TERT Promoter

Research progress of BRAFV600E and TERT promoter mutations coexistence in papillary thyroid cancer

The Role of TERT Promoter Mutations in Postoperative and Preoperative Diagnosis and Prognosis in Thyroid Cancer.

TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis

Relationship between BRAF V600E mutation, cervical lymph node metastases and extrathyroidal ;extension in papillary thyroid carcinoma

Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer

Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.

Relationship Between BRAF V600E Gene Mutation and the Clinical and Pathologic Characteristics of Papillary Thyroid Microcarcinoma.

Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations—a meta-analysis

Role of Ultrasonographic Features and Quantified BRAFV600E Mutation in Lymph Node Metastasis in Chinese Patients with Papillary Thyroid Carcinoma